Skip to main content
Clinical and Translational Science logoLink to Clinical and Translational Science
. 2025 Feb 15;18(2):e70155. doi: 10.1111/cts.70155

Participant‐Centered Engagement for Sustained Adherence to Smartwatches: A 12‐Month Prospective Decentralized Digital Health Study

Angelina R Wilton 1,2, Christina T Saliba 1,2, Jean Marrero‐Polanco 1, Katharine Sheffield 3, Quantia Wilkes 4, Miriam Anacker 4, Paul E Croarkin 5, Mohit Chauhan 6, Liselotte N Dyrbye 7, Sherry Chesak 8,9, William V Bobo 4,6,10, Arjun P Athreya 1,2,5,✉
PMCID: PMC11829698  PMID: 39954233

ABSTRACT

Adherence in digital health studies with extended observation periods (≥ 12 months) is limited, and participant retention considerably reduces with time. The US Food and Drug Administration has issued guidelines for improving participant engagement, adherence, and diversity in digital health studies combined with decentralized procedures. A decentralized digital health study on well‐being was designed with protocolized procedures to study the feasibility of participant engagement and technology support to facilitate adherence (wearing the smartwatch ≥ 70% of time) sustained over a 12‐month period. At the end of the study, participants were asked about their ease of participation and free‐response questions about how wearing the smartwatches impacted their physical wellness. An inductive thematic analysis (ITA) was performed to assess themes of those responses and association with adherence. A total of 298 participants were recruited between 2022 and 2023 (n = 129 in Cohort A in October 22, n = 169 in Cohort B in April 23), with 23% non‐white participants accrued. Among the 298 participants accrued, 273 (92% of accrued participants) completed the 12‐month study with an average overall adherence of 77.4% (SD = 32.64) wear‐time across 12 months. Median adherence of participants whose responses exemplified an ITA theme encompassing perceived behavior changes in sleep and physical activity was higher than those who did not have a response exemplifying that theme. Conversely, those expressing perceived discomfort or intrusiveness of the smartwatch had a statistically lower adherence. These results highlight the crucial roles of technology support and robust engagement efforts to enable sustained adherence over extended follow‐up periods in decentralized digital health studies.

Keywords: decentralized study, digital health, engagement, smartwatch, wellness


Summary.

  • What is the current knowledge on the topic?
    • ○
      Digital health studies utilizing wearables (e.g., smartwatches) are often met with low engagement (i.e., increased dropouts and limited participant diversity) and sustained adherence (i.e., device utilization over extended observation periods).
    • ○
      The U.S. Food and Drug Administration provided guidelines to enhance participation and study adherence.
  • What question did this study address?
    • ○
      Would a decentralized study protocol with participant‐centric engagement procedures achieve improved participant diversity and sustained adherence to wearing a smartwatch for extended study periods (i.e., 12 months)?
  • What does this study add to our knowledge?
    • ○
      The study results suggest that protocol‐driven methods of engaging study participants may be important factors behind the observed high levels of study completion and smartwatch adherence.
    • ○
      Perceived behavior changes (in the context of wellness) were associated with higher adherence, while feelings of discomfort and intrusiveness of the watch were associated with lower adherence.
  • How might this change clinical pharmacology or translational science?
    • ○
      This study highlights the crucial roles of technology support and robust engagement efforts to enable sustained adherence over extended follow‐up periods in decentralized digital health studies for studying patient well‐being or functioning in response to drug treatment.

Abbreviations

DHTs

digital health technologies

FDA

Food and Drug Administration

FTE

full time effort

IQR

interquartile range

IRB

Institutional Review Board

ITA

Inductive Thematic Analysis

RN

Registered Nurse

SD

standard deviation

STROBE

Strengthening the Reporting of Observational Studies in Epidemiology

US

United States

1. Introduction

The 2019 pandemic accelerated the adoption of decentralized procedures and digital health technologies (DHTs) in clinical trials to reduce the need for in‐person visits to clinical trial sites [1]. Decentralized procedures range from remote recruitment efforts to electronic consents and tele‐ or video follow‐ups [2]. DHT combines software and hardware technologies to remotely deliver interventions or monitor human functioning [3]. The combination of decentralized procedures with DHTs is expected to improve participant diversity by reducing some of the logistical and financial barriers to participating in clinical trials [4].

Smartwatches are a ubiquitous form of DHT currently being studied in many health contexts as they are easy to deploy to remotely assess physical activity, sleep, heartrate, and other metrics [5]. Prior studies reported low adherence with smartwatches, particularly in longitudinal studies lasting greater than 3 months, which in turn limits data that can be used to identify biomarkers or design interventions [6, 7, 8, 9, 10]. Post hoc analyses of such studies identified several operational and human factors affecting adherence. The adherence‐limiting factors included discomfort from wearing the study device, burden on the part of participants for charging devices, dissatisfaction with the study‐issued smartphone's operating system (e.g., Android vs. iOS), and inadequate responsiveness to technology issues [7, 10, 11, 12]. Several recommendations by the US Food and Drug Administration and others have since been made to integrate proactive participant engagement and technology response management into study protocol to improve adherence in using DHTs [13, 14, 15, 16].

This study team designed a decentralized, prospective digital health study (see Figure 1A) and hypothesized that participant‐centered engagement efforts would enable sustained adherence and dropout rates over 12 months of follow‐up [17]. Participants were hospital‐based registered nurses (RNs) recruited to wear a study‐issued smartwatch for 12 months. The choice of RNs as participants was motivated by historic levels of burnout, which are among the highest for all healthcare professions, coupled with a high risk for developing depression and increasing attrition from the field [18, 19]. The prevalence rate of major depressive disorder (MDD) in RNs is twice as high as that of the general public and the second highest suicide rate (16.0 per 100,00 persons) among healthcare professionals [20, 21]. This study was further motivated by the results of a systematic review of wearables for studying burnout and well‐being in healthcare professionals, which highlighted low adherence and high attrition rates [10], indicating a need for innovative participant‐centric engagement strategies to better study these populations.

FIGURE 1.

FIGURE 1

(A) Study Engagement Schedule and Data Management Overview, (B) Example Monthly Newsletter, (C) and Example Quarterly Summary Card.

Adherence was defined as participants wearing the device ≥ 70% of the time in a 24 hour day. The threshold for adherence in this study was based on the adherence needed in continuous monitoring of physiological and biological measures with DHTs for meaningful imputation [22, 23, 24]. This study assessed the feasibility of protocol‐driven engagement procedures to sustain adherence. The protocol‐driven engagement procedures prior to accrual were (i) pre‐recruitment remote townhall‐styled presentations and (ii) electronic consent (e‐consent); and postaccrual were (i) a simplified enrollment manual for installing the smartwatch for study measurements, (ii) monthly newsletters and townhall‐styled conference presentations conveying study progress, (iii) quarterly individualized smartwatch data summary cards, (iv) issuance of comfortable watch bands, and (v) an 18‐h monitored email to respond to technology issues. Given that the commodity smartwatches such as the one used in this study are commercially marketed to promote physical wellness [25, 26, 27], this study additionally tested the association of smartwatch adherence with participant‐perceived factors that limit or improve their perceived physical wellness.

2. Methods

2.1. Study Design and Participants

This was a 12‐month decentralized, prospective digital health study focused on the well‐being of hospital‐based RNs who were expected to wear a study‐issued smartwatch and complete quarterly electronically disseminated surveys (key details of the study, sample size calculations, and measurements are described elsewhere [17]). The study was approved by the Mayo Clinic Institutional Review Board (IRB) and is registered as NCT05481138 on clinicaltrials.gov. Preaccrual engagement strategies included advertising the study through unit presentations and flyers on bulletin boards with a QR code linking to an online form to express interest in participation. Eligible participants were hospital‐based RNs aged between 22 and 70 years of age and employed ≥ 60% full‐time effort (FTE) at Mayo Clinic. Upon assessing for eligibility, interested participants electronically completed informed consent (e‐consent). Participants were recruited in two cohorts, namely Cohort A (October 1, 2022–October 1, 2023) and Cohort B (April 1, 2023–April 1, 2024) as part of the aims of a larger study that is described elsewhere [17]. After completing the surveys in quarters 1, 2, 3, and 4, participants were remunerated $25, $50, $50, and $75 respectively, and an additional $20/quarter if the watch was worn ≥ 70% of the time during the respective quarter. Exemptions from wear time reminders and adherence included instances if participants were experiencing technical issues or personal extenuating circumstances (e.g., family emergencies). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist was used as a guide for the reporting of this study.

2.2. Decentralized Enrollment of Smartwatches

Upon signing consent, participants were notified via email of the location where they could pick up their study supply bag and complete setup by the start of the 12‐month observation period. The bag included a new smartwatch (Garmin Vivoactive4 (for Cohort A) and Venu2Plus (for Cohort B)—compatible with both Android and iOS phones and has up to 7‐day battery life after full charge), a study reminder postcard affixed to a refrigerator magnet, and a manual designed by the study team (Supporting Information S3: Setup Manual) to guide the participant through the watch setup process that ends in connecting the watch's data to a cloud‐based data aggregation service (Fitabase by SmallSteps LLC). Participants were deemed accrued into the study and eligible for receiving study surveys once their watch's data stream was confirmed in Fitabase. Should a participant leave the institution after enrollment, they were allowed to continue for the remainder of the study duration with an additional consent following turnover.

2.3. Outcomes

Towards assessing the effectiveness of study engagement procedures, the primary outcome was adherence (measured on the smartwatch). Adherence was defined as the percentage of time over a 24 h day in which the study‐issued smartwatch detected a pulse. Persistent nonadherence was defined as the wear time ≤ 10%. Complete cases were defined as the individual days (24 h periods) that a participant wore the watch both during the day and at night.

Participants were asked to complete an online survey after 12 months of participation that assessed the following additional domains inspired in part by the FDA's guidelines for studies with DHTs:

2.3.1. Smartwatch Familiarity

Participants were asked to inform their familiarity with smartwatches prior to participating in the study, with the responses being, “not at all familiar”, “slightly familiar”, “somewhat familiar”, “moderately familiar”, or “extremely familiar”.

2.3.2. Ease/Difficulty in Participating in the Decentralized Study

Participants were asked to inform their perception on the ease or difficulty in participating in the decentralized study, with the responses being, “very difficult”, “somewhat difficult”, “neutral”, “somewhat easy”, and “very easy”.

2.3.3. Participant perception of smartwatch on physical wellness

Participants were asked the following: “Physical Wellness is defined as the balance between physical activity, healthy foods, and sleep for ideal health and functioning. Reflecting on the past 12 months, can you describe ways in which the smartwatch might have improved or hindered your physical wellness?” Participants were given two free response text boxes, labeled “improved” and “hindered”.

2.3.4. Adverse Effects

Adverse Effects were reported by participants in the email distribution list provided during enrollment. The time the team received notification of the issue and the time that the problem was resolved were documented for each case.

2.4. Decentralized Participant‐Centered Engagement Procedures

2.4.1. Additional Watch Accessories

Anticipating potential discomfort with or aesthetic preferences for smartwatch bands and lost charging cables, a box of watch bands was placed in nurse stations comprising several options in terms of material (e.g., silicone, stretchy nylon, etc.), sizes, and designs. These bands were replenished monthly. A charging station (a power strip with four charging cables) was provided in nursing units to facilitate the charging of smartwatches during shifts.

2.4.2. Monthly Newsletters at the Cohort Level

IRB‐approved monthly newsletters (an example in Figure 1B and Supporting Information S1) emailed to all active participants featured (i) aggregate statistics of data collection and study adherence, (ii) study announcements of upcoming surveys, (iii) a simplified synchronization (for the watch to send data to Fitabase via their smartphone) reminder, (iv) watch features of potential interest to participants, and (v) a user‐experience anecdote from a participant.

2.4.3. Monthly Town Hall‐Styled Presentations on Study Progress

Study investigators delivered IRB‐approved videoconference presentations with preliminary data analyses and study announcements to participants every quarter in their respective work units. Participants had the opportunity to ask questions about study progress, seek help for technology issues, and provide feedback on improving the comfort or usability of the study device.

2.4.4. Quarterly Individualized Watch Data Summary Cards

With an IRB‐approved format, on the 15th day after a study quarter, a one‐page summary (see an anonymized example in Figure 1C) of the participant's data on percent of time the watch worn (adherence), total miles walked per month, average hours of sleep per calendar day, and median resting heart rate, maximum and minimum heart rates were provided via email.

2.4.5. Proactive Monitoring

The study team monitored for data streaming from all smartwatches on Fitabase and reminded participants via email to synchronize their smartwatch with Garmin's Connect mobile app if their data were not seen for over 14 days [17].

2.4.6. Technical Support Procedures

The study team established an 18 h/day monitored email address for participants to communicate any watch‐related issues, and a log was developed to document issues/resolutions. Within 24 h of receiving the email, a study team member reviewed the issue and provided a solution via email or scheduled a time with the participant to provide personalized assistance. Malfunctioning watches or lost watches (one time) were replaced with a new watch at no cost to the participant.

2.4.7. Addressing Adverse Effects

Within 24 hours of receiving a report of an adverse reaction, study investigators evaluated the condition and advised the participant accordingly. If a rash or other reaction from the device was reported, participants were encouraged to discontinue wearing the device until the issue was resolved.

2.5. Analyses

2.5.1. Preprocessing

Missing values from continuous or ordinally scaled items were imputed via the median of the sample for the value. Missingness in categorical items or long‐response items were omitted from the analysis. Participants who were persistently nonadherent (adherence ≤ 10%) or exempt from wear‐time monitoring were omitted from wear‐time analyses. Individuals who dropped out of the study were included in calculating adherence up until the month prior to dropping out of the study.

2.5.2. Survival analyses

By defining retention as the number of months a participant completes in the 12‐month study, survival analyses were used to assess the likelihood of study completion. Kaplan–Meier curves were used to compare the retention rates between Cohorts A and B. The association of adherence over 12 months with smartwatch familiarity prior to study participation was assessed using the Kruskal–Wallis test.

2.5.3. Adherence and Sociodemographic Factors

The effects of sociodemographic factors on adherence were evaluated using a linear mixed effects model. The sociodemographic factors included in the model were age, sex assigned at birth, marital status, race, and smartwatch familiarity prior to the study. The model included a random intercept for Study ID, the model was fit using restricted maximum likelihood (REML), and t‐tests employed Satterthwaite's approximation for degrees of freedom.

2.5.4. Inductive Thematic Analysis (ITA) for qualitative responses on participant perceptions about their physical wellness in the context of wearing a smartwatch for a year

The ITA was chosen to qualitatively assess the perception of the study's impact on participants. Two independent reviewers (SC and JMP) read participant responses for each open‐ended question and grouped questions into broader “themes” and labeled participant responses with corresponding themes. Reviewers discussed conflicting results with a third reviewer (APA) to obtain consensus. Wilcoxon rank‐sum tests with Bonferroni corrections for multiple comparisons were used to assess differences in adherence within each theme. Demographic factors associated with adherence were then evaluated to assess statistical associations with the derived themes. Fisher exact tests were employed with Monte Carlo simulations (10,000 replicates) to approximate p values to correct for sparse or zero counts in contingency tables.

3. Results

3.1. Baseline Characteristics, Enrollment, and Prior Familiarity With Smartwatches

A total of 298 participants were accrued in two rounds of recruitment: Cohort A and Cohort B. In Cohort A, out of 141 participants assessed for eligibility, 137 e‐consents were delivered via email, with a total of 129 participants accrued in the study (see consort diagram in Figure 2). In Cohort B, out of the 212 participants assessed for eligibility, 188 e‐consents were delivered via email, with a total of 169 participants accrued in the study. Across both cohorts, the mean age of participants was 33 years (IQR = 27, 41), and 83% of participants were assigned female at birth. Twenty‐one percent of participants identified as non‐White (see Table 1 for cohort characteristics). There were no significant differences in major demographic factors examined between the cohorts (p > 0.05) (Table 1).

FIGURE 2.

FIGURE 2

Consort diagram for Cohort A (October 2022–October 2023) and Cohort B (April 2023–April 2024). [Correction added on 22 February 2025, after first online publication: Maternity leave has been removed from Cohort A in Figure 2].

TABLE 1.

Cohort demographics.

Overall a (n = 298) Cohort A a (n = 129) Cohort B a (n = 169) p b
Age in years 33 (27, 41) 33 (26, 39) 35 (27, 43) 0.2
Sex at birth
Female 247 (83%) 107 (83%) 141 (84%) 0.7
Male 50 (17%) 22 (17%) 27 (16%)
Unknown 1 0 1
Marital status
Now married, registered domestic partnership, or civil union 172 (59%) 81 (63%) 91 (55%) 0.5
Single 94 (32%) 37 (29%) 57 (34%)
Divorced 17 (5.8%) 6 (4.7%) 11 (6.6%)
Separated 6 (2%) 3 (2.3%) 3 (1.8%)
Other 5 (1.7%) 1 (0.8%) 4 (2.4%)
Unknown 4 1 3
Highest degree or level of school related to nursing
Bachelor's degree (e.g., BA, BS) 205 (69%) 91 (71%) 114 (69%) 0.3
Associate degree (e.g., AA, AS) 52 (18%) 23 (18%) 29 (17%)
Master's degree (e.g., MA, MS, MEng, Med, MSW, MBA) 22 (7.5%) 11 (8.5%) 11 (6.6%)
Nursing diploma 8 (2.7%) 3 (2.3%) 5 (3%)
Professional degree beyond bachelor's degree (e.g., MD, DO, DDS, DVM, LLB, JD) 2 (0.7%) 1 (0.8%) 1 (0.6%)
Doctorate degree (e.g., PhD, EdD, DNP) 6 (2.0%) 0 (0%) 6 (3.6%)
Unknown 3 0 3
Ethnicity
Hispanic or Latino 16 (5.6%) 8 (6.5%) 8 (4.8%) 0.5
Not Hispanic or Latino 272 (94%) 115 (93%) 157 (95%)
Unknown 10 6 4
Race
White 228 (79%) 101 (81%) 127 (77%) 0.6
Asian 31 (11%) 11 (8.9%) 20 (12%)
Black or African American 11 (3.8%) 3 (2.4%) 8 (4.8%)
American Indian/Alaska Native 3 (1%) 1 (0.8%) 2 (1.2%)
More than one race 15 (5.2%) 8 (6.5%) 7 (4.2%)
Unknown 8 5 3
Shift type
100% day shift 159 (59%) 73 (63%) 86 (56%) 0.5
100% night shift 53 (20%) 22 (19%) 31 (20%)
Flex shift 56 (21%) 20 (17%) 36 (24%)
Unknown 30 14 16
a

n (%); Median (IQR).

b

Wilcoxon rank‐sum test, Pearson's chi‐squared test, Fisher's exact test.

With smartwatch delivery beginning a month before the start date of the cohort, 96% and 97% of Cohort A and Cohort B participants were able to onboard independently using the setup manual provided (see Supporting Information S3: Setup Manual), with the remainder seeking assistance via email or phone to complete the setup. Out of the 259 respondents, 42 (16%) stated that they were “not at all familiar” with smartwatches before study participation, while 44 (17%) stated they were “slightly familiar”, 56 (22%) stated they were “somewhat familiar”, 61 (24%) said they were “moderately familiar”, and 56 (22%) stated they were “extremely familiar”. The participants' smartwatch familiarity before the study did not differ significantly by cohort (p > 0.05); however, the median age of participants varied by differing levels of familiarity (p = 0.002). The median age of those who responded “extremely familiar” was 31 (IQR: 26, 40), whereas those who responded “not at all familiar” had a median age of 39 (IQR: 30, 49), indicating that individuals older in age tended to be less familiar with the smartwatches on average compared to younger individuals. The wear time over the study duration was not associated with differing levels of familiarity with smartwatches before the study (p > 0.05, see Supporting Information S2, Table S1).

3.2. Study Completion and Ease of Participation in Decentralized Study

For Cohort A and Cohort B, 89% (115 out of the 129 accrued participants) and 93% (158 out of the 169 accrued participants) of participants in respective cohorts completed the 12‐month study, with an overall retention rate of 92% (no significant difference in the probability of survival between cohorts (p > 0.05), see Kaplan–Meier curve in Supporting Information S2, Figure S2). Sixteen and 20 participants in Cohort A and Cohort B, respectively, continued in the study following their leaving the institution.

In both cohorts, the most frequently recorded reasons for dropout were leaving the institution and lack of follow‐up thereafter (n = 9), preference for another wearable device (n = 7), nonadherence (n = 5), sensory difficulties with the device (n = 2), no longer meeting eligibility (n = 1), and one participant experienced an allergic reaction to the watch (n = 1). There were no significant differences in demographic factors (p > 0.05) between those who dropped out from the study in both cohorts and those who remained enrolled (see Supporting Information S2, Table S3).

When asked about their ease of participation at the end of the year on an ordinal scale (n = 272), 51% and 25% of participants said that study participation was “Very Easy” and “Somewhat Easy”, respectively (see Figure 3D). Thirteen percent of participants chose a “Neutral” response, while 11% of participants said that participation was either “Very Difficult” or “Somewhat Difficult”. Responses to this question varied by race (p = 0.02) and cohort (p = 0.019), but these differences disappeared above the set alpha of 0.05 when adjusting for multiple comparisons (see Supporting Information S2, Table S4).

FIGURE 3.

FIGURE 3

(A) Average wear time of study participants by month. Wear time is defined as the percent of time the participant wore the watch on their wrist over a 24 h period. Average wear time was aggregated by month. Persistently noncompliant and exempt participants were removed for each month and are outlined in Supporting Information S2, Table S5. Error bars represent ±SEM of mean wear time each month. (B) Average wear time of complete cases (defined as days where individuals wore the watch during the day and at night) per month. Participants who dropped out of the study were removed from wear‐time statistics the month they departed. Error bars represent ±SEM of mean wear time for complete cases each month. (C) Recorded technical issues encountered throughout both cohorts during their time in the 12‐month study (n = 76) and (D) end‐of‐study ease of participation (n = 272).

3.3. Adherence

The average adherence (smartwatch worn) among all participants in both cohorts during the 12‐month study was 77.44% (SD = 32.64) in a 24 h day and remained ≥ 70% (expected adherence benchmark) for all months of the year for both cohorts (see Figure 3A). Cohort A's overall wear time was 75.09% (SD = 33.23) and Cohort B's overall wear time was 79.10% (SD = 32.11). Forty‐three out of 115 participants (37%) in the first cohort and 83 out of 160 participants (52%) in the second cohort who completed the study in full wore the watch ≥ 70% of the time for 12 consecutive months. The adherence of active participants by each month is reported in Supporting Information S2, Table S5. In Cohort A, a range of 87–114 participants (depending on study month) qualified as completed cases, whereas a range of 133–160 participants qualified as complete cases in Cohort B (Supporting Information S2, Table S6). In both cohorts, complete cases had an average wear time of 93.62% (see Figure 3B). When overall adherence was adjusted for key demographics and social determinants of health factors, race was the only significant factor (β = 6.90, SE =3.33, t = 2.07, p = 0.04) (Supporting Information S2, Table S7), with higher average wear time observed in participants who identified as white (79.3%, SD = 21.6) compared to participants who did not identify as white (73.6%, SD = 24.9%), while both achieved > 70% adherence in the study.

3.4. Characteristics of Wearable‐Related Technical Issues and Adverse Effects

3.4.1. Technical Issues

There were 76 technical issues recorded across both cohorts of the study (see Figure 3C). The mean time to resolution of the issue was 1.27 days (SD = 2.98 days). The response time depended on the study team's ability to identify the right technical solution, public holidays, or wait times for additional support/guidance from Garmin International. Twenty‐five devices were replaced across both cohorts. The most common issues for devices that needed replacement included software issues (28%), hardware issues (20%), and smartwatch loss (20%). Other issues (22%) that necessitated replacement included battery issues, Bluetooth connection issues, and skin irritation.

3.4.2. Adverse Effects

Five incidents of adverse effects were reported by five unique participants, all of which involved skin irritation in areas where the watch was worn. Except for one participant in Cohort B (see Figure 2), the other four participants continued in the study following the resolution provided by the study team.

3.5. Inductive Thematic Analysis of Perceived Benefits and Hindrances of Wearables on Physical Wellness in a 12‐Month Period

The summary and number of themes derived in the ITA from the free‐text responses are summarized in Table 2 with definitions and example responses exemplifying the respective theme. Responses that were labeled as “No Improvement” or “No Hindrance” indicated that participants did not experience improvements or hindrances to their physical wellness from the device. The ITA also allowed for responses to comprise multiple themes.

TABLE 2.

ITA response themes associated with overall wear‐time adherence.

Open‐ended question Response ITA theme, response theme description, and example quote from a participant Response theme present? (Y/N, n) Median [IQR] overall wear time Raw p
Reflecting on the past 12 months, can you describe ways in which the smartwatch might have improved or hindered your physical wellness? (IMPROVED) Promotes Overall Health Awareness—the device being advantageous for participants in that it promotes mindfulness of their physical activity, stress, and sleep and included mentions of the feedback watches provided. “Seeing that when I drink alcohol my sleep and my stress were affected in a negative way helped me. I have increased my physical activity regardless of the watch. But seeing the stats helped encourage me”.—Female participant aged in the 30 s Y (n = 160) 90.6 [82.1–99.0] 0.96
N (n = 74) 85.2 [71.4–99.0]
Behavior Changes in Sleep and Physical Activity—indicating the motivation to pursue physical activity, meet sleep goals, or reduce stress. Some responses included reflections on their perceived behavioral changes, whereas others discussed their motivation to pursue certain goals within different aspects of wellness. “I definitely consumed less alcohol. I exercised more (even increased my walking). Tried to keep a better sleep schedule”.—Female participant aged in the 50 s Y (n = 89) 90.6 [82.1–99.0] 0.03*
N (n = 145) 85.2 [71.4–99.0]
Improved Well‐Being and/or Self‐Care—the device increasing personal accountability for various aspects of well‐being or a positive life experience associated with the device. “I stopped drinking energy drinks [and] stopped taking a weight loss med[ication]…”—Male participant aged in the 30 s Y (n = 83) 88.3 [77.5–99.1] 0.18
N (n = 151) 85.2 [73.9–96.5]
No Improvement—indicating that the participants did not experience benefits to their physical wellness from the device. “My watch did not improve my physical wellness”.—Female participant aged in the 30 s Y (n = 8) 78.6 [68.4–88.8] 0.13
N (n = 226) 87.5 [76.7–98.3]
Reflecting on the past 12 months, can you describe ways in which the smartwatch might have improved or hindered your physical wellness? (HINDERED) No Hindrance—indicating that the participants did not experience hindrances to their physical wellness from the device. “I wouldn't really say anything was hindered from my viewpoint. Maybe battery life? But having the chargers at work made it really easy to get charged up quickly”.—Female participant aged in their twenties Y (n = 92) 89.6 [81.0–98.2] 0.04*
N (n = 120) 84.9 [71.2–98.7]
Discomfort—the device being physically uncomfortable to wear. Some responses cited discomfort while sleeping, while others cited discomfort while exercising or working. “Wearing the watch to sleep was difficult [because] I like to sleep on my stomach with my hands under my face/head and the watch would be in the way or the light would come on. I was however able to turn the light off which allowed me to sleep better”.—Female participant aged in their 30 s Y (n = 51) 79.3 [60.1–98.4] 0.004 **
N (n = 161) 88.4 [79.8–97.0]
Intrusiveness—sentiments about devices impeding aspects of their lifestyle. Participants cited notifications and the watch itself as being distracting, annoying, and/or stressful and discussed impacts on primarily sleep and work. “The model of the watch that we had to use can be somewhat annoying. It kept vibrating when the phone [was] disconnected and connected. [I was] missing important notifications in my phone since [the watch] gets disconnected easily even though the phone is within the recommended distance to the watch. The idea of having to change the sleeping schedule in the app can be too much to track my sleep quality, especially for a night shifter with kids”.—Female participant aged in the 30 s Y (n = 22) 81.0 [62.8–99.2] 0.03*
N (n = 190) 87.9 [77.1–98.7]
Discouragement—sentiments of the watch acting as a source of stress or discouragement about one's situation. “It was discouraging to see steps on days [that] I was feeling lazy and didn't walk or do many activities”.—Female participant aged in the 20 s Y (n = 43) 88.0 [77.9–98.1] 0.29
N (n = 169) 87.1 [76.0–98.2]
Metric Inaccuracies—personal reservations about the accuracy of the watch data. “[The watch] did not accurately record my sleep or stress—which I found frustrating. If I was lying awake at night, struggling to sleep, the watch thought I slept all night. If I was feeling incredibly stressed, because I have a naturally low heart rate, the watch did not pick up my stress. I found this discouraging because I wanted to make sure that my participation in the study helped demonstrate the difficulties we face”.—Female participant aged in the 30 s Y (n = 20) 91.0 [88.1–93.9] 0.13
N (n = 192) 86.1 [73.2–98.9]

Note: p values calculated by the Wilcoxon rank‐sum test. Bolded values indicate significant p values after Bonferroni correction. Y, yes; N, no.

*

p < 0.05.

**

p < 0.01.

“Reflecting on the past 12 months, can you describe ways in which the smartwatch might have improved your physical wellness?”: Participant Response Themes. The 220 responses (87% response rate) to this question were grouped into four themes, “Promotes Overall Health Awareness” (66% of responses), “Behavior Changes in Sleep and Physical Activity” (40% of responses), “Improved Wellbeing and/or Self‐Care” (37% of responses), and “No Improvement” (3.6% of responses).

“Reflecting on the past 12 months, can you describe ways in which the smartwatch might have hindered your physical wellness?”: Participant Response Themes. The 198 responses (78% response rate) to this question were grouped into five themes, including “No Hindrance” (45% of responses), “Discomfort” (22%), “Intrusiveness” (9.1%), “Discouragement” (20%), and “Metric Inaccuracies” (9.1%).

3.6. Smartwatch Adherence and Themes Relating to Improving or Hindering Physical Wellness in a 12‐Month Period

The median adherence in participants reporting behavior activation was higher (though not reaching statistical significance after correcting p value for multiple comparisons) than that of those who did not based on themes relating to the improved physical wellness after wearing a smartwatch for 12 months. The median adherence (across 12 months) of participants whose responses comprised the “Behavior Changes in Sleep and Physical Activity” theme was 5.4% higher than that of those who did not have a response exemplifying that theme (see Table 2). Additionally, those responses comprising the “Discomfort” theme had a 9.1% lower wear time on average compared to those whose responses did not, and similarly, those whose responses comprising the “Intrusiveness” theme had a 6.9% lower wear time on average compared to those that did not (see Table 2). Theme responses did not vary by race, a factor that was significant in its association with year‐long adherence with smartwatches (Supporting Information S2, Tables S7 and S8).

4. Discussion

In this 12‐month decentralized digital health study that accrued a total of 298 participants, over 90% of the accrued participants completed the study with an adherence (wear time of smartwatch) of 77.4%. Over three‐quarters of the participants considered the study participation “Somewhat Easy” or “Very Easy”. Qualitative results suggested that perceived behavior changes (in the context of physical wellness) were associated with higher adherence, whereas feelings of discomfort and intrusiveness of the watch were associated with lower adherence. Taken together, these results suggest that protocol‐driven methods of engaging study participants may be factors that facilitate sustained levels of smartwatch adherence and study completion rates.

The Food and Drug Administration (FDA) has provided guidance regarding participant accrual, engagement, and retention strategies in studies that use DHTs and decentralized protocols [16, 28]. Particularly, from the perspective of decentralized studies, the FDA guidance emphasized the broadening of participation through different media of advertising the study and providing appropriate technology support while accommodating different mobile technology ecosystems (e.g., Android vs. iOS mobile operating systems) [28]. Additional emphasis was placed on the need to make the studies participant‐centric by focusing on human factors relating to (a) continual feedback with measurements made, (b) environmental factors (e.g., temperature, humidity) that affect comfort and therefore usability of DHTs, (c) proactive monitoring mechanisms for data missingness, and (d) understanding battery life and charging needs. Prior studies have often cited these human factors in challenging the adherence using wearables as examples of DHTs [7, 11, 12]. This study's intent was to incorporate participant engagement into our protocol, a priori, to facilitate sustained adherence in extended observational periods (12 months) with low dropout rates (≤ 30%). Although we do not randomize participants to engagement versus nonengagement strategies, our results still provide strong evidence linking intentional, participant‐centered engagement efforts with high adherence.

The demographics of those who enrolled in the study were generally similar to the US national nursing population [29], except our sample was generally younger and included more individuals who identified as male (17% vs. 12% in the US nursing workforce [30]). Our sample also included nurses who worked a variety of shifts represented (59% day, 20% night, and 21% flex workers) comparable to the US nursing workforce (30% working night‐shift [31]). This diversity in our accrued participants may be due to our decentralized recruitment procedures, aligned with suggestions from the US FDA on how to conduct decentralized clinical trials [28], and the use of a study smartwatch agnostic to the user's smartphone operating system (Apple Inc.'s iOS vs. Google Inc.'s Android) with a long battery life [32].

The monthly newsletter and town‐hall styled updates that provided aggregate statistics about study progress, along with the quarterly watch data summary cards that provided a personalized report of one's average metrics, may likely have contributed to the high, sustained adherence. Our finding aligns with prior studies demonstrating that engagement with participants on study progress and their own data is associated with increased odds of retention and improvements in physical activity [12]. Access to a variety of watch bands that could be suited to various lifestyles and preferences may also have promoted comfort for sustained adherence. Strategies such as these may be critical to ensuring adequate engagement in DHT, as studies without them have seen upwards of 50% of participants either stop using the wearable or drop from a 12‐month study [7, 10]. Additional strategies to promote wear time worth evaluating include those that focus on improving comfort and lessening intrusiveness (e.g., perceptions of the watch being distracting, annoying, and/or stressful) as this was associated with lower wear time. Additional industry‐academic partnerships may be warranted to promote user trust in data, as 9.1% of participants reported a lack of trust in measurements in open‐ended responses, which agrees with prior qualitative studies of wearables [33, 34].

Other components of this study that may have contributed to high engagement include the 18 h/day monitored email with prompt response, charging stations, spare accessories (e.g., cables, bands, adapters), and replacement devices in the event of technology issues. These approaches likely minimized participants' time in the study without a functioning device. A recent study with smartwatches cited technical issues being the most prominent determinant for individuals ceasing long‐term use of the device [7]. Citing Statista, the US Chamber of Commerce reported that while 70% of US consumers expect a same‐day solution to their product's problems in customer service, only 46% of consumers are willing to wait up to 3 business days for a solution [35]. While academic institutions may not have the resources to staff a 24/7 customer service team, an operational email distribution list and a running document of watch‐specific issues and solutions in this study facilitated a mean resolution time of 1.27 days across 76 incidents.

4.1. Limitations

This study was conducted at a single institution and included only inpatient nurses who were, on average, younger and more likely to be male than the US nursing population. Additionally, it was conducted post‐pandemic when nurse burnout has been at a historical high, potentially contributing to high enrollment in the study as nurses seek ways to improve how they are feeling [25]. Future studies are needed to explore the impact of the engagement procedures in this study in other cohorts of study participants using experimental, randomized designs. Additionally, this study was limited to the use of one smartwatch vendor; therefore, it does not reflect technology management challenges that would likely occur in studies that expand beyond one vendor. As not all differences in adherence within themes relating to factors improving or hindering physical wellness achieved statistical significance (while indicating intuitive directionality in differences) in the reported exploratory analyses, larger cohorts in the future could be designed that are powered for specific effect sizes in adherence difference relating to behavior activation or self‐efficacy. Finally, future work should elucidate patterns of physical activity and sleep improvements that associate with themes derived in the ITA.

4.2. Conclusions

In a 12‐month decentralized digital health study on the wellness of RNs, participant‐centric engagement procedures achieved 77.4% adherence in wearing a smartwatch, with 92% of participants (among 298 accrued) completing all study procedures. Participant engagement procedures included monthly newsletters of study progress, a personalized quarterly summary of smartwatch data, and 18‐h technology support. Higher adherence was associated with participants who utilized data to promote behavior changes to improve their wellness.

Author Contributions

A.R.W., A.P.A., and W.V.B. wrote the manuscript. A.P.A., W.V.B., P.E.C., M.C., S.C., and L.N.D. designed the research. A.R.W., C.T.S., K.S., M.A., Q.W., A.P.A., M.C., W.V.B., and S.C. performed the research. A.R.W., C.T.S., J.M.‐P., S.C., and A.P.A. analyzed the data. All authors reviewed and approved the final version of the manuscript.

Conflicts of Interest

Dr. Bobo has received grant or research support from the Mayo Clinic, NIH, National Science Foundation, the Watzinger Foundation, and the Myocarditis Foundation. He has contributed chapters to UpToDate concerning the pharmacological management of bipolar depression. Dr. Croarkin has received grant or research support from the Mayo Clinic, NIH, National Science Foundation, Brain and Behavior Foundation, and Pfizer Inc. He has received a research grant for a multicenter trial from Neuronetics Inc. He has received in‐kind equipment support from Neuronetics Inc. and Magventure Inc. for investigator‐initiated studies funded by NIH. He received in‐kind support (supplies and genotyping) from AssureRX for an investigator‐initiated study. He has served on the advisory boards for Engrail Therapeutic Inc. and Sunovion Inc. He served as a consultant to Meta Platforms Inc. Dr. Dyrbye has received royalties from CWS Inc. for the Well‐being Index licensed by the Mayo Clinic outside the submitted work. No other disclosures were reported. Dr. Athreya has received grant or research support from the Mayo Clinic, NIH, National Science Foundation, the Watzinger Foundation, and the Blue Gator Foundation. Dr. Chauhan serves as a Board member of Here Tomorrow (volunteer, noncompensated) and a member of the medical advisory board of Clarity Telehealth Inc. All other authors declared no conflicts of interest for this work.

Supporting information

Figure S1.

CTS-18-e70155-s003.pdf (446.6KB, pdf)

Data S2.

CTS-18-e70155-s002.pdf (634.8KB, pdf)

Data S3.

CTS-18-e70155-s001.pdf (2.1MB, pdf)

Acknowledgments

The authors thank all subjects for their participation in this study. We also thank Dr. Abu Minhajuddin, Professor in the Peter O'Donnell Jr. School of Public Health and the Department of Psychiatry at University of Texas Southwestern for consulting on statistical methods relating to the inductive thematic analyses presented in this work. We thank Dr. Kathleen Yost, Wendy Daniels, Corina Moreno, and Christina Smith (Mayo Clinic Survey Research Center) for their help in planning, testing, and implementing the survey. We also thank Tim Mahle and Nick Evans (Mayo Clinic Supply Chain Management), Dr. Leila Jones (Mayo Clinic Center for Individualized Medicine), Sena Christianson (Mayo Clinic Office of Clinical Trials), Mayo Clinic Risk Management Team, and Mayo Clinic Clinical Trials Beyond Walls for their support.

Funding: This work is supported in part by the National Institute of Nursing Research Award (R01 NR020362), National Institutes of Health Predoctoral T32 Fellowship GM144233, Graduate Research Education Program (GREP), and The Center for Individualized Medicine at Mayo Clinic. The funding sources, Small Steps LLC (Fitabase), and Garmin International played no role in the study design; collection; management; analyses and data interpretation; preparation, review, or approval of the manuscript and the decision to submit the manuscript for peer review and publication.

Data Availability Statement

Code is available on request. Data requests can be made to Mayo Clinic Ventures and will be reviewed per Mayo Clinic data management policies upon the completion of the entire study.

References

  • 1. De Brouwer W., Patel C. J., Manrai A. K., Rodriguez‐Chavez I. R., and Shah N. R., “Empowering Clinical Research in a Decentralized World,” NPJ Digital Medicine 4, no. 1 (2021): 102, 10.1038/s41746-021-00473-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Rogers A., De Paoli G., Subbarayan S., et al., “A Systematic Review of Methods Used to Conduct Decentralised Clinical Trials,” British Journal of Clinical Pharmacology 88, no. 6 (2022): 2843–2862, 10.1111/bcp.15205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Smuck M., Odonkor C. A., Wilt J. K., Schmidt N., and Swiernik M. A., “The Emerging Clinical Role of Wearables: Factors for Successful Implementation in Healthcare,” NPJ Digital Medicine 4, no. 1 (2021): 45, 10.1038/s41746-021-00418-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Sehrawat O., Noseworthy P. A., Siontis K. C., Haddad T. C., Halamka J. D., and Liu H., “Data‐Driven and Technology‐Enabled Trial Innovations Toward Decentralization of Clinical Trials: Opportunities and Considerations,” Mayo Clinic Proceedings 98, no. 9 (2023): 1404–1421, 10.1016/j.mayocp.2023.02.003. [DOI] [PubMed] [Google Scholar]
  • 5. Izmailova E. S., Wagner J. A., and Perakslis E. D., “Wearable Devices in Clinical Trials: Hype and Hypothesis,” Clinical Pharmacology & Therapeutics 104, no. 1 (2018): 42–52, 10.1002/cpt.966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Harari G. M., Müller S. R., Mishra V., et al., “An Evaluation of Students' Interest in and Compliance With Self‐Tracking Methods: Recommendations for Incentives Based on Three Smartphone Sensing Studies,” Social Psychological and Personality Science 8, no. 5 (2017): 479–492. [Google Scholar]
  • 7. Hermsen S., Moons J., Kerkhof P., Wiekens C., and De Groot M., “Determinants for Sustained Use of an Activity Tracker: Observational Study,” JMIR mHealth and uHealth 5, no. 10 (2017): e7311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Mekhael M., Noujaim C., Lim C. H., et al., “Compliance Challenges in A Longitudinal COVID‐19 Cohort Using Wearables for Continuous Monitoring,” Cardiovascular Digital Health Journal 3, no. 4 (2022): S25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Wang W., Harari G. M., Wang R., et al., “Sensing Behavioral Change Over Time: Using Within‐Person Variability Features From Mobile Sensing to Predict Personality Traits,” Proceedings of the ACM on Interactive, Mobile, Wearable and Ubiquitous Technologies 2, no. 3 (2018): 1–21. [Google Scholar]
  • 10. Barac M., Scaletty S., Hassett L. C., et al., “Wearable Technologies for Detecting Burnout and Well‐Being in Health Care Professionals: Scoping Review,” Journal of Medical Internet Research 26 (2024): e50253, 10.2196/50253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Zhang Y., Pratap A., Folarin A. A., et al., “Long‐Term Participant Retention and Engagement Patterns in an App and Wearable‐Based Multinational Remote Digital Depression Study,” NPJ Digital Medicine 6, no. 1 (2023): 25, 10.1038/s41746-023-00749-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Brakenridge C. L., Fjeldsoe B. S., Young D. C., et al., “Evaluating the Effectiveness of Organisational‐Level Strategies With or Without an Activity Tracker to Reduce Office Workers' Sitting Time: A Cluster‐Randomised Trial,” International Journal of Behavioral Nutrition and Physical Activity 13, no. 1 (2016): 115, 10.1186/s12966-016-0441-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Apostolaros M., Babaian D., Corneli A., et al., “Legal, Regulatory, and Practical Issues to Consider When Adopting Decentralized Clinical Trials: Recommendations From the Clinical Trials Transformation Initiative,” Therapeutic Innovation & Regulatory Science 54, no. 4 (2020): 779–787, 10.1007/s43441-019-00006-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Hamm M. E., Arnold J., Denson J., et al., “The ACTIV‐6 Stakeholder Advisory Committee: A Model for Virtual Engagement in Decentralized Clinical Trials,” Journal of Clinical and Translational Science 7, no. 1 (2023): e264, 10.1017/cts.2023.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Jeong H., Kim H., Kim R., Lee U., and Jeong Y., “Smartwatch Wearing Behavior Analysis: A Longitudinal Study,” Proceedings of the ACM on Interactive, Mobile, Wearable and Ubiquitous Technologies 1, no. 3 (2017): 1–31. [Google Scholar]
  • 16. Administration USDoHaHSFaD , “Digital Health Technologies for Remote Data Acquisition in Clinical Investigations,” 2023 Guidance for Industry, Investigators, and Other Stakeholders.
  • 17. Wilton A. R., Sheffield K., Wilkes Q., et al., “The Burnout PRedictiOn Using Wearable aNd ArtIficial IntelligEnce (BROWNIE) Study: A Decentralized Digital Health Protocol to Predict Burnout in Registered Nurses,” BioMed Central Nursing 23, no. 1 (2024): 114, 10.1186/s12912-024-01711-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Sullivan D., Sullivan V., Weatherspoon D., and Frazer C., “Comparison of Nurse Burnout, Before and During the COVID‐19 Pandemic,” Nursing Clinics of North America 57, no. 1 (2022): 79–99, 10.1016/j.cnur.2021.11.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Galanis P., Moisoglou I., Katsiroumpa A., et al., “Increased Job Burnout and Reduced Job Satisfaction for Nurses Compared to Other Healthcare Workers After the COVID‐19 Pandemic,” Nursing Reports 13, no. 3 (2023): 1090–1100, 10.3390/nursrep13030095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Letvak S., Ruhm C. J., and McCoy T., “Depression in Hospital‐Employed Nurses,” Clinical Nurse Specialist 26, no. 3 (2012): 177–182, 10.1097/NUR.0b013e3182503ef0. [DOI] [PubMed] [Google Scholar]
  • 21. Olfson M., Cosgrove C. M., Wall M. M., and Blanco C., “Suicide Risks of Health Care Workers in the US,” Journal of the American Medical Association 330, no. 12 (2023): 1161–1166, 10.1001/jama.2023.15787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Bergenstal R. M., “Understanding Continuous Glucose Monitoring Data,” in Role of Continuous Glucose Monitoring in Diabetes Treatment (American Diabetes Association, 2018). [PubMed] [Google Scholar]
  • 23. Braem C. I. R., Yavuz U. S., Hermens H. J., and Veltink P. H., “Missing Data Statistics Provide Causal Insights Into Data Loss in Diabetes Health Monitoring by Wearable Sensors,” Sensors (Basel) 24, no. 5 (2024): 1526, 10.3390/s24051526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Di J., Demanuele C., Kettermann A., et al., “Considerations to Address Missing Data When Deriving Clinical Trial Endpoints From Digital Health Technologies,” Contemporary Clinical Trials 113 (2022): 106661, 10.1016/j.cct.2021.106661. [DOI] [PubMed] [Google Scholar]
  • 25. Aloweni F., Ayre T. C., Teo I., Tan H. K., and Lim S. H., “A Year After COVID‐19: Its Impact on Nurses' Psychological Well‐Being,” Journal of Nursing Management 30, no. 7 (2022): 2585–2596, 10.1111/jonm.13814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Thompson W. R., “Worldwide Survey of Fitness Trends for 2019,” ACSM Health Fitness J 22, no. 6 (2018): 10–17. [Google Scholar]
  • 27. Wahl Y., Düking P., Droszez A., Wahl P., and Mester J., “Criterion‐Validity of Commercially Available Physical Activity Tracker to Estimate Step Count, Covered Distance and Energy Expenditure During Sports Conditions,” Frontiers in Physiology 8 (2017): 725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Food and Drug Administration , “Decentralized Clinical Trials for Drugs, Biological Products, and Devices: Draft Guidance for Industry, Investigators, and Other Stakeholders,” 2023.
  • 29. Smiley R. A., Allgeyer R. L., Shobo Y., et al., “The 2022 National Nursing Workforce Survey,” Journal of Nursing Regulation 14, no. 1 (2023): S1–S90.37012978 [Google Scholar]
  • 30. Bureau of Health Workforce, H. R. S. A. , “2022 National Sample Survey of Registered Nurses,” 2022. https://bhw.hrsa.gov/sites/default/files/bureau‐health‐workforce/Nurse‐Survey‐Fact‐Sheet‐2024.pdf.
  • 31. Zhang Y., Murphy A., Lammers‐van der Holst H. M., Barger L. K., and Duffy J. F,, “Night Shift Work and Sleep Experiences in Older Night Shift Nurses,” Western Journal of Nursing Research 2024 Nov 13:1939459241299779. 10.1177/01939459241299779. Epub ahead of print. PMID: 39535119. [DOI] [PubMed] [Google Scholar]
  • 32. Peterson N. E., Bate D. A., Macintosh J. L., and Trujillo Tanner C., “Wearable Activity Trackers That Motivate Women to Increase Physical Activity: Mixed Methods Study,” JMIR Forms and Research 7 (2023): e48704, 10.2196/48704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Cho S., Ensari I., Weng C., Kahn M. G., and Natarajan K., “Factors Affecting the Quality of Person‐Generated Wearable Device Data and Associated Challenges: Rapid Systematic Review,” JMIR mHealth and uHealth 9, no. 3 (2021): e20738, 10.2196/20738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Chamorro‐Koc M., Peake J., Meek A., and Manimont G., “Self‐Efficacy and Trust in Consumers' Use of Health‐Technologies Devices for Sports,” Heliyon 7, no. 8 (2021): e07794, 10.1016/j.heliyon.2021.e07794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Commerce USCo , “Customer Service Guide,” 2023.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Figure S1.

CTS-18-e70155-s003.pdf (446.6KB, pdf)

Data S2.

CTS-18-e70155-s002.pdf (634.8KB, pdf)

Data S3.

CTS-18-e70155-s001.pdf (2.1MB, pdf)

Data Availability Statement

Code is available on request. Data requests can be made to Mayo Clinic Ventures and will be reviewed per Mayo Clinic data management policies upon the completion of the entire study.


Articles from Clinical and Translational Science are provided here courtesy of Wiley

RESOURCES